Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2276 June 2025

| APPLICANT (stamp or sticker acceptable) | | | PATIENT NHI: | REFERRER Reg No: | |
|---|--|---|---|---|--|
| Reg No: | | | First Names: | First Names: | |
| Name: | | | Surname: | Surname: | |
| Address: | | | DOB: | Address: | |
| | | | Address: | | |
| Fax Number: | | | | Fax Number: | |
| Pertuzumab | | | | | |
| Initial application — metastatic breast cancer Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate) | | | | | |
| | and | The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) | | | |
| | Patient is chemotherapy treatment naïve Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 more between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer | | | | |
| | | | | | |
| | and The state of t | | | | |
| | The patient has good performance status (ECOG grade 0-1) and | | | | |
| Pertuzumab to be administered in combination with trastuzumab | | | | | |
| | and | Pertuzumab maximum first dose o | f 840 mg, followed by maximum of 420 mg every 3 w | eeks | |
| | | Pertuzumab to be discontinued at | disease progression | | |
| Renewal — metastatic breast cancer | | | | | |
| Current approval Number (if known): | | | | | |
| Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate) | | | | | |
| | | The patient has metastatic b | reast cancer expressing HER-2 IHC 3+ or ISH+ (incl | uding FISH or other current technology) | |
| | | The cancer has not progress | sed at any time point during the previous 12 months v | whilst on pertuzumab and trastuzumab | |
| | or | | | | |
| | | Patient has previously discordisease progression | ntinued treatment with pertuzumab and trastuzumab | for reasons other than severe toxicity or | |
| | | Patient has signs of disease | progression | | |
| | | | during previous treatment with pertuzumab and trast | uzumab | |

I confirm the above details are correct and that in signing this form I understand I may be audited.